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Abstract
Innovation lies at the heart of academia, and universities generate high-quality, intellectual property on a large scale.
However, commercial translation of this intellectual property has traditionally been poor, particularly in the critical
healthcare sector. It is critical that this situation is addressed to ensure that innovation from research institutes can fulfil
its potential and progress to have a genuine impact on the outside world. In this article, we consider the nature of
healthcare innovation in academia and ways in which commercial translation of intellectual property can be successfully
realised. This is first analysed from an academic perspective, with a particular focus on how academic motivations and
work practices can shape successful translation. We then switch perspective to examine the same process from an
industry perspective, looking at the characteristics and expectations involved in the innovation life cycle. To place these
analyses in context, we present a case study examining a project being undertaken to commercialise a novel surgical
instrument, the intra-abdominal platform, from identification of clinical need, through the development life cycle, to com-
mercialisation of the system. We reflect on the successes and challenges encountered during the intra-abdominal plat-
form project, the broader lessons learned and in conclusion use these to emphasise how academia can adopt practices
to better translate intellectual property in the future.
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Introduction: commercialising the
intellectual property generated in
universities
Innovation lies at the heart of academia, and universi-
ties generate intellectual property (IP) on a large scale.
The standard of that IP is often high and that IP is of
interest to the private sector, as demonstrated by the
fact that start-ups spun out of universities are more
successful than other start-ups.1,2 However, the rate at
which spins-out companies are formed, or IP is success-
fully licensed, varies dramatically between universities.3
While all universities generate lots of invention
disclosures and patents, not all universities generate
lots of licences and spin-outs.4
Commercialising innovations, often called the trans-
lation of research, has not historically been seen as a
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strength of universities and other research organisa-
tions, with limited success and efficiency evident.5 Only
half of recommended healthcare practices are actually
implemented,6,7 and it often takes upwards of 15 years
for research findings to be fully translated into
improved practice in the healthcare field.8 The barriers
to translation are various and interrelated and include
inadequate design of research programs9 (e.g. research
not being designed to be easily adopted by the health-
care setting, or inadequate marketing of the idea to the
setting so they do not quickly and easily see the benefits
of the new idea), regulations being too onerous or pol-
icy dictating what interventions are adopted.10 The
word ‘translation’ hints at one of the problems, which
is the difficulty of translating the innovative idea11
from the language of the researcher to the language
understood by the practitioner.12
With these factors in mind, we now consider the
nature of innovation in academia and what factors gov-
ern successful translation, first from an Academic per-
spective and second from an Industry perspective. We
then present a case study of a project to commercialise
a surgical support device, reflecting on the successes,
challenges and lessons learned.
Translating academic innovation: an
academic perspective
Some academics are wary of commercialisation and
have reservations about the impact it may have on
research, thinking it something which goes against their
ideals of sharing knowledge with other researchers
across the globe. The sharing of ideas, and joint inno-
vation brought about by wide collaborations, ‘open
innovation’, is a modern way to innovate. Large com-
panies like Procter & Gamble are advocating the use of
global innovation networks, saying, for example ‘Times
have changed, and the world is more connected. In the
areas in which we do business, there are millions of
scientists, engineers and other companies globally. Why
not collaborate with them?’ and even calling for new
product ideas from the general public on their web-
site.13 It is generally accepted that, today, collaboration
leads to better innovation.14
Interestingly, the open innovation model is
adopted by many large companies by means of forming
networks of trusted research partners, rather than
being absolutely open.14,15 It is important to be able to
trust your partners, to be of the same mind-set and
not be competitors. It is also important not to have
such a large network that the research project becomes
overly complex from an IP point of view; with every
new research partner involved on a project, the com-
plexity of the IP and contractual arrangements
increases.
When it comes to commercialising innovations, uni-
versity academics need to strike a balance between
being open and sharing ideas, and protecting their ideas
and IP, in order to exploit them commercially. The
commercialisation of their ideas is important, as it is
the pathway by which end-users actually get to enjoy
the benefits of the innovations, but given that compa-
nies need to invest in the idea, often quite heavily,
before they can take it to market, commercialisation of
an idea requires an element of secrecy. The secrecy
allows the company to obtain a patent, or other form
of IP protection, and gain a period of at least a few
years’ exclusivity before copycat products flood the
market. Technology Transfer Offices in universities
must reassure their academics that commercialisation
can sit happily alongside research excellence and the
sharing of knowledge. There is a need to reassure that
patenting can sit alongside publishing provided the uni-
versity provides the appropriate support mechanisms
for timely and effective management of IP.
It takes time to commercialise ideas and many aca-
demic institutions now employ a Technology Transfer
Office to help the academic hone their entrepreneurial
skills and guide them through the various steps of the
translation process. In particular, the market research,
economics, IP assessment, and marketing are all critical
in taking the idea to the stage where a company will
invest in it.
The modern ‘open innovation’ networking model
can be adopted by universities, just as it is being by
companies. The network should be as wide as possible
without becoming unwieldy. On the scale of the indi-
vidual research project, a good project team will be
multidisciplinary, to cover all bases, and will include (in
the healthcare field) academics, healthcare professionals
(the end-users), companies (medical device companies
and private sector product designers), IP professionals
and an innovation manager to market the idea to com-
panies. It is also important to include patients or
patient groups, who will ensure that the device is some-
thing they would be happy having used on them. The
research needs to be designed for the healthcare practi-
tioners: that is, it must ensure that the product is easy
for them to adopt, cost effective for them to adopt and
its benefits need to be clearly explained to them in a
way which they can quickly and easily understand. To
achieve this mode of translation requires all the talents
of a multidisciplinary team.6,14
Translating academic innovation: an
industry perspective
Clearly, academia and universities are centres for learn-
ing, but they are also hubs for innovation. The innova-
tion context can range from being highly exploratory,
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for example, cancer cell therapies, through to a more
commercially aligned approach, for example, creating
solutions to solve an immediate and specific clinical
need.
Research academics may adopt different approaches
to innovation. Some researchers may have no desire, or
need, to work with industry while for others it is stan-
dard practice. In the case of the former, the researchers
perhaps create an open innovation platform whereby
their work is published and used by collaborating uni-
versities on pioneering, long-term innovation. Another
category of academics are those who have a desire to
commercialise their innovations but perhaps do not
understand or appreciate the amount of resources or
funds required in order to migrate their piece of aca-
demic research into a commercially viable proposition.
In this context, there is a need to better communicate
what is required and the amount of time and effort
needed. Finally, a growing group of academics have a
desire to commercialise their innovations and under-
stand and appreciate the need for industry engagement.
In this context, they are accepting of a holistic and col-
laborative approach with a team of stakeholders with
different skills and experiences, all with the common
desire and goal of migrating the innovation into
industry.
Universities are becoming more focused on commer-
cialising their innovations. There are various platforms
in which this can be achieved. For example, some uni-
versities have commercialisation facilities whereby the
employees are focused on engaging with industry in
order to create working relationships to develop the
commercialisation of university innovations. This can
result in licensing technology or perhaps creating a
spin-out company which has a commercial focus. A
typical successful example of this is Xiros Ltd which is
one of the 100 spin-out companies that has been pro-
duced by the University of Leeds since 1995. Currently,
44 of these spin-out companies are active in areas as
diverse as oil exploration, cancer drug development,
geological research, embryology and foetal develop-
ment.16 Other universities create a platform strategy by
which they have an attitude towards open innovation.
This can be a peer-to-peer collaborative approach
between universities or university and industry. A
prime example is Manchester University who devel-
oped and published their research on Graphene. They
have subsequently capitalised by becoming an interna-
tional centre for Graphene-related research.17
In healthcare, the National Health Service (NHS)
have identified a need for universities to be encouraged
to commercialise innovations. There is a better oppor-
tunity for success if the university academics create a
partnership with industry. The National Institute for
Health Research (NIHR) was created to improve
patient and service outcomes through research which
may include creating and fostering relationships
between universities and industry and subsequently
offering assistance in managing the process. The NIHR
also have the ability to fund collaborative projects
whereby the migration to success is increased. One such
example is the Invention for Innovation (i4i) pro-
gramme which has been successfully applied to the IAP
project.
What does innovation look like? The reality
Innovation, by its very nature, can be planned or
unplanned and the success or failure can be attributed
to many factors. The innovation process requires a hol-
istic approach with an appropriate blend of stake-
holders which include academics and industry. The
Gartner Hype Cycle18–20 is a popular description of the
innovation process,21 plotting expectations against time
(Figure 1). After the initial ‘Trigger’ in which a project
is conceived, there follows a ‘Peak of Inflated
Expectation’, Trough of disillusionment, Slope of
enlightenment and finally a Plateau of Productivity. A
familiar point of failure with a project is commonly
known as the ‘Valley of Death’. This is the critical
point within an academically driven project whereby
engagement with industry can be misaligned, misunder-
stood or lost. There are many cases within Universities
whereby this is commonplace, and it is the responsibil-
ity of industry-focused academics and University com-
mercialisation departments to avoid these situations.
Clearly, all University-driven projects will have dif-
ferent challenges and opportunities when considering
the commercialisation process. However, for successful
translation, there needs to be a point within a project
whereby the innovation migrates from a University
push to an industry pull. There are many reasons why
an otherwise potentially successful innovation can die
Figure 1. An adapted graphical depiction of the Gartner Hype
Cycle, showing different regions of the innovation process.18
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in the ‘Valley of Death’. For example, the budget
requirements required may not be sufficiently realised
or could be inappropriately utilised; the stakeholders,
managers and person resource may be inexperienced or
lack the necessary focus; the technology could become
compromised or obsoleted with the innovation process
if protracted; new and emerging IP could circumvent
the innovation; competing products could migrate to
market quicker and if successfully marketed would
reduce the commercial success of other subsequent
innovation. It is worth highlighting that while it is easy
to identify the characteristics and causes of the Valley
of Death, it is not necessarily so easy to avoid. In the
next section, we present our own experiences of this
phenomenon and reflect that, in the context of the
Gartner Hype Cycle, the activity of academic and
industry partnerships is critical if projects are to move
through the Trough of Disillusionment to a successful
outcome.
Case study: commercial translation of the
intra-abdominal platform surgical system
To illustrate the challenges inherent in translating
healthcare innovation from academic to commercial
impact, we present a case study on the intra-abdominal
platform (IAP), a new surgical instrument for retrac-
tion in laparoscopy being developed by the authors.
The IAP system began as the result of discussions
between colorectal surgeons and engineers at the
University of Leeds, working together on a variety of
projects under a Surgical Technologies research theme.
A natural outcome of these close working relationships
was identification of clinical needs in minimally inva-
sive surgery (MIS) that could be addressed through
engineering innovation.
Background
The advent of MIS has revolutionised clinical practice
over the past decade with proven benefits in terms of
less postoperative pain,22–24 shorter hospital stays,25–27
quicker return to normal function, fewer wound com-
plications and improved cosmesis.28 The continued
implementation of this technique has resulted in predic-
tions that 60%–90% of all general surgical procedures
will be performed using this technology in the future.29
However, the application of MIS presents significant
challenges due to the fact that the surgeon’s hands are
replaced by laparoscopic/endoscopic instruments to
visualise and interact with tissues. These are manipu-
lated from outside the body cavity and limit dexterous
movements, visualisation and navigation, thus creating
a significant learning curve for MIS which acts as a
barrier, limiting adoption of MIS.
A key part of any operation is to ensure adequate
exposure to the operating field by repositioning and
retracting surrounding tissues, thus enabling the sur-
geon to effectively visualise and perform the intended
procedure safely.30,31 In MIS, retraction is made diffi-
cult by the restrictive environment of the closed body
cavity and a lack of suitable instrumentation. Typical
practice involves an assistant holding and manipulating
tissues under supervision of the lead surgeon but this is
highly operator dependent. Other solutions have been
proposed, ranging from the use of nylon sutures to
retract tissues and organs,32,33 mechanical ‘hooking’
devices34,35 to more exploratory methods such as the
use of externally controlled magnetic retractors.30
However, current practice in MIS has seen minimal
uptake of these approaches, and there is therefore a
well-defined clinical need, and commercial opportunity,
for the development of a retraction system for MIS.
The IAP development cycle
Development of the IAP is now considered using the
Gartner Hype Cycle model, as the project moves from
identification of clinical need through to the point of
commercialisation, as illustrated in Figure 2.
Trigger: from clinical need to concept. The trigger for this
research work was in identifying a clinical need for
improved retraction in MIS. To better understand, and
define, the clinical need, we developed a series of user
needs, summarised below:
 The retraction system should be ‘hands-free’
(thereby enabling a surgeon to concentrate on
the operation in progress without dependency
on an assistant).
Figure 2. Key points of IAP development mapped to the
Gartner Hype Cycle.
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 The system should be able to quickly and reli-
ably retract a variety of tissues in the abdominal
cavity.
 The device should support MIS principles
(deployed and used with minimal trauma to the
patient).
 The system should not obstruct existing surgical
processes or instrumentation.
This trigger phase is characterised by rapid develop-
ment and an associated increase in expectations. This
was particularly true for the IAP. A small team of engi-
neers considered the user needs and a conceptual solu-
tion was developed in which a collapsible structure
could be used to provide a ‘scaffold’ within the abdom-
inal cavity, as summarised in Figure 4. From this con-
cept, a series of functional prototypes were developed
to explore key design parameters such as size and mate-
rial selection. The team quickly arrived at a finalised
conceptual design (Figure 3), for which a set of detailed
design requirements were developed from the initial
clinical user needs. These specifications encompassed
considerations of size (its cross section must be compa-
rable to existing MIS instrumentation for atraumatic
insertion) and strength (it should be sufficiently strong,
rigid and stable to retract a typical human liver). A full
prototype design was then developed to meet the design
requirements and a physical prototype fabricated
through in-house workshop facilities, to positive feed-
back from our clinical advisors. Encouraged by these
successes, a patent application was developed and filed
to protect the IP (PCT/GB2011/051415, EP 2595548
A1) surrounding the concept and design.
Inflated expectations. Following the promising outcomes
of the trigger phase, the team secured 1 year’s funding
from the EPSRC Medical Technologies Innovation and
Knowledge Centre (IKC) to begin commercialisation
of the IAP system. This involved accelerating develop-
ment by expanding the core team to bring in dedicated
expertise in medical device design (Pd-m International),
fabrication (Sheffield Precision Medical Ltd) and inno-
vation managers in the IKC. This expanded team
worked to further refine the prototype, improving key
aspects of functionality, for example introducing a low-
profile clamping mechanism which helps minimise
interference with other surgical tools.
At the culmination of the technical development
process, an animal study was conducted to evaluate the
surgical efficacy of the system. Here, a single porcine
model was used in an MIS procedure with the IAP pro-
viding retraction for a range of tissues within the
abdominal cavity, including gall bladder, small bowel
and liver. The study was valuable in two respects: first,
it highlighted a number of limitations that should be
addressed in future developments (e.g. ensuring the
operative field is sufficiently covered by the scaffold
system); second, it demonstrated that the IAP concept
has surgical utility.
The peak of expectation was reached when a second
round of funding was secured to further develop the
IAP. The funding was awarded by the UK NIHR
through the ‘Invention for Innovation’ scheme (Ref: II-
LA-0214-20003), designed to catalyse translation of
healthcare technologies such as the IAP.
Trough of disillusionment. Commencing the NIHR-funded
phase of IAP development represented a turning point
in the project; the aims of the work were to develop a
full commercial package for the IAP system. This
required consideration of additional factors, notably
Healthcare Economic Modelling, Design for
Manufacture and supporting future regulatory
approval. There was a corresponding need to expand
the team to provide this expertise and undertake a criti-
cal assessment of the project in these domains. The out-
come was a transition into the ‘Trough of
Disillusionment’ as the process highlighted two signifi-
cant challenges in realising a commercially viable
product.
The challenges facing the IAP centred on assump-
tions made early in the development life cycle that it
Figure 3. The IAP concept: (a and b) The IAP is inserted through the abdominal wall in a collapse low-profile state, (c) after
insertion the IAP is opened to provide a scaffold and clamped from above and (d) the clamped IAP arms provide a scaffold for tissue
retraction using custom magnetised clips.
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should be a reusable surgical instrument, as opposed to
a disposable single-use device, based on informal analy-
sis of trends in the world market. Healthcare Economic
analysis highlighted that a reusable instance of the IAP
might be commercially unviable for a manufacturer
and retailer. In conjunction, a technical reappraisal of
the system using rigorous Failure Mode and Effects
Analysis ‘FMEA’ principles raised concerns around the
multitude of small articulated joints in the system.
These made it difficult to manufacture and assemble at
tolerance, present a significant challenge for repeat
cleaning and sterilisation and are vulnerable to corro-
sion and device failure.
This marked the nadir of our journey through the
Hype Cycle; our system had demonstrated technical
and clinical merit but was poorly suited for commercial
translation into clinical use. It was evident that a new
approach was required to deliver a single-use IAP sys-
tem designed for manufacture.
Slope of enlightenment. To successfully progress from this
critical point in the project, our team committed to an
iterative collaborative design cycle. This included all the
project’s key stakeholders in order to ensure that the
resultant system was technically, clinically and commer-
cially viable. Our approach is summarised in Figure 4.
The redesign process was initiated by revisiting our
User Needs and associated Design Requirements, from
which a series of new concepts were produced by indus-
try partners Pd-m. Crucially, these designs were con-
ceived to consider aspects such as ease of manufacture
and sterilisation from the outset. A collaborative design
cycle was now followed to refine the designs, and key
inputs included the following:
 Mechanical analyses. Finite element modelling
and experimental testing to ensure structural
integrity.
 Health economic modelling. Detailed analysis to
understand market headroom constraints.
 Clinical evaluation. Cadaveric models were used
to ensure redesigns were clinically appropriate.
 Design for manufacture. Designs were developed
for plastic injection-moulding production.
The outcome of this process was a design which dif-
fered substantially from the original concept; the multi-
tude of metallic articulated joints which formed the
IAP expansion mechanism are replaced by a telescopic
arm assembly and the entire assembly is manufactured
using polymer injection moulding. The result is a low-
cost, robust, clinically appropriate single-use system. In
addition, our new approach has generated additional
IP, free from prior art that may limit freedom to oper-
ate, and this has been protected through a UK patent
filing. Overall, this provides a significantly improved
package for commercial translation which is now our
focus as we look towards commercial licensing deals in
the Plateau of Productivity.
Discussion
The IAP case study presented above highlights that the
realities of innovation and in particular the translation
of healthcare technologies from academia to industry is
rarely a straightforward process. However, with the
benefit of hindsight, it is useful to reflect on the suc-
cesses and challenges that have arisen during the IAP
project.
Figure 4. A collaborative design cycle was used to take our (a) initial IAP design into (b) an iterative redesign with University of
Leeds (UoL), design consultants (Pd-m) and clinicians (LTHT) to develop (c) the optimised telescopic IAP.
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Moving along the innovation pathway, from idea
towards commercial product, is a complex process. In
the context of medical devices, this requires develop-
ment in areas spanning technical development and
manufacture, clinical efficacy, regulatory approval and
commercial viability. Accordingly, effective healthcare
innovation requires a team with a multidisciplinary
skillset able to address these varied areas of develop-
ment. It is evident that few academic institutions, let
alone individual researchers, possess all these skillsets.
Thus, rather than adopting a unilateral approach, a
more efficient model is to adopt a collaborative multi-
disciplinary approach that encompasses academia,
industry and clinical inputs. Our work on the IAP proj-
ect highlights the virtues of this multidisciplinary,
multi-partner approach in which we adopted a colla-
borative design cycle to enable responsive, adaptive
development, but arguably a more efficient approach
would be to have employed the collaborative design
cycle from the start of the project as summarised in
Figure 4. No single member of the group could have
conducted this breadth of work individually, the com-
bined effort of the team was therefore critical to our
success.
It should be noted that a multi-partner approach
also brings its own particular challenges, as compared
to working individually. The team must be managed to
ensure their endeavour is coordinated, constructive and
clearly defined. Central to this is effective communica-
tion, in particular ensuring that the role of each stake-
holder is clearly defined and equally that they
appreciate the skills, experience and roles of the other
stakeholders in the team. In the context of the IAP
project, this was manifest in linking our design-cycle
activities (Figure 4); conceptual designs from industry
designers were critically evaluated by university
researchers and then passed for end-user appraisal with
patients and clinicians. This requires the outputs from
each stage of work to be clearly defined (e.g. does ‘pro-
totype’ mean a computer-aided design (CAD) model or
functional physical prototype?), delivered in a timely
fashion (to ensure critical deadlines are met) and com-
municated effectively. Communication is particularly
relevant in the context of healthcare innovation
because it depends on close engagement of end-users,
both patient and healthcare professionals. An inherent
advantage of the multi-partner approach is that it pro-
motes communication between these stakeholders and
end-users, helping to ensure all parties are involved in
the process.
An interesting consequence of using a collaborative
model for innovation is that the academic(s) who origi-
nally conceived and developed an idea must necessarily
play a smaller role as part of a larger multidisciplinary
team. The size of this role is also likely to decrease as
the project moves through the life cycle towards
commercialisation. For a long-term project like the
IAP, this also necessitates funding to not just build but
maintain a team for the entirety of the project (which
may span multiple funding rounds). This may conflict
with traditional academic models of research practice
in which the lead researcher remains in close control of
their research, rather than ‘handing it on’. However, if
academia is to improve its record of translating health-
care innovation, this seems a very necessary step and
one which will bring benefits to all partners, from aca-
demic, through industry and ultimately benefit health-
care. In our experience, this requires trust among the
team and recognition that the skills, experiences and
motivations of academic and industry stakeholders dif-
fer, but are complementary. Academics are typically
driven by the conception of new ideas while industry
stakeholders are by definition more commercially dri-
ven. It is the combination of these entities, sustained
over time, which promotes effective innovation, as
highlighted in Figure 5.
In our case study, we detail the innovation pathway
of the IAP system in reference to stages of the Gartner
Hype Cycle which provides an interesting framework
to consider the evolution of a technology, in particular
helping to reflect on periods of challenge and ways in
which these may be overcome in the future. Early prog-
ress in our project was rapid, moving quickly from
identification of the clinical need through conceptual
design to a functional prototype. The resultant design
provided a working solution which demonstrated the
efficacy of using a device for tissue retraction in MIS.
However, there was little consideration of future com-
mercialisation in this process which ultimately forced
us to redesign the IAP system. This highlights two
important aspects for effective translation. First, in this
instance, we were fortunate to have the resource and
expertise available to perform a redesign, but arguably
a more efficient approach would be to have employed
the collaborative design cycle far earlier in the project.
Second, technology can only be developed successfully
if the team are receptive to change, reacting to the
needs of the project without prejudice from their per-
sonal attachment to particular concepts or ideas. In
both these aspects, our experience has shown that a col-
laborative multidisciplinary approach can help identify
and avoid potential barriers to innovation, helping
move the project through ‘valley of death’ towards
commercial success.
Conclusion
In this article, we have examined the relationship
between academia and innovation. Traditionally,
researchers at universities have not been strong at
translating their research towards commercial impact,
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a result of many factors including professional motiva-
tions, knowledge of the innovation process and expec-
tations of outcomes. However, it is encouraging to note
that this trend is shifting through the promotion of
academic–industry partnerships and improved aca-
demic support systems to facilitate innovation
translation.
The Gartner Hype Cycle provides a useful frame-
work with which to critically analyse the process and
highlighted those periods of particular challenge for the
project were classic hurdles to innovation. While these
can be readily identified post hoc, it is less easy to iden-
tify and overcome these challenges during the course of
a project, which may lead to projects failing in the so-
called innovation ‘valley of death’. It is therefore cru-
cial to adopt appropriate working practices which help
mitigate these risks to successful technology transla-
tion. Our experience with the IAP project has shown
that using a multidisciplinary collaborative approach,
harnessing the expertise of industry, academic research-
ers and clinicians, is a powerful means to achieve this
and can help facilitate improved translation of health-
care technologies from academia to industry.
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